Macrophage Cell Therapy Cuts Death and Transplant Risk in Half for Cirrhosis Patients
A 4-year follow-up of a phase 2 trial finds autologous macrophage therapy nearly halves death or transplant rates in liver cirrhosis.
Summary
Liver cirrhosis affects millions globally, and liver transplant remains the only proven cure for end-stage disease. A phase 2 clinical trial called MATCH01 tested whether injecting patients' own immune cells — macrophages grown from their blood monocytes — could reduce liver inflammation, reverse scarring, and stimulate regeneration. In a long-term follow-up extending up to four years, patients who received macrophage therapy had a 30.8% rate of death or transplant, compared to 58.3% in those receiving standard care alone. Treated patients also gained an average of 252 additional days of survival without transplant. No serious safety concerns were linked to the cell therapy. These results mark a significant step forward for regenerative approaches to liver disease.
Detailed Summary
Liver cirrhosis — the end stage of chronic liver disease driven by fibrosis and inflammation — kills hundreds of thousands annually and strains transplant systems worldwide. Until now, liver transplantation has been the only curative option, yet donor organ availability is critically limited. A regenerative medicine approach using patients' own immune cells may be changing that calculus.
The MATCH01 trial (ISRCTN10368050) tested autologous macrophage therapy in cirrhosis patients. Investigators harvested monocytes from each patient's own blood, differentiated them into macrophages in the lab, and reinfused them. Preclinical evidence had shown macrophages can dampen hepatic inflammation, promote fibrosis resolution, and support liver regeneration — all key processes in reversing or slowing cirrhosis progression.
The long-term follow-up of the phase 2 arm, now published in Cell Stem Cell, extends observation to up to four years post-randomization. The headline result is striking: only 30.8% of macrophage-treated patients died or required transplant during the follow-up window, versus 58.3% in the standard medical care group. Treated patients accumulated an additional 252 days of transplant-free survival on average. No increased rate of serious adverse events was attributed to the cell therapy, reinforcing the safety profile established in the earlier phase 1 data.
These findings carry significant implications for regenerative medicine and hepatology. If validated in larger trials, autologous macrophage therapy could become a meaningful bridge or alternative to transplantation — a prospect with enormous clinical and health-economic value given the global shortage of donor livers.
Important caveats apply. The trial was relatively small, and this summary is based on the abstract alone; full statistical details, patient numbers, and subgroup analyses await review of the complete manuscript. Several authors also hold advisory or financial relationships with Resolution Therapeutics, a company commercializing this technology, warranting scrutiny of potential bias.
Key Findings
- Macrophage-treated patients had a 30.8% death or transplant rate vs. 58.3% in standard care over 4 years.
- Treated patients gained an average of 252 additional transplant-free survival days.
- No serious adverse events were attributed to the autologous cell therapy.
- Therapy uses patients' own monocyte-derived macrophages to reduce fibrosis and promote liver regeneration.
- Results support advancing macrophage-based regenerative strategies toward larger confirmatory trials.
Methodology
MATCH01 was a phase 1/2 randomized clinical trial of autologous monocyte-derived macrophage infusions versus standard medical care in patients with liver cirrhosis. A long-term follow-up study re-enrolled phase 2 participants and extended observation to up to 4 years from randomization. Primary endpoint was a composite of death or liver transplantation.
Study Limitations
This summary is based on the abstract only; full patient numbers, statistical confidence intervals, and subgroup analyses are unavailable without access to the complete manuscript. The trial sample size appears small, limiting statistical power and generalizability. Multiple authors have financial conflicts of interest with Resolution Therapeutics, which is commercializing this macrophage platform.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.